Congress Asset Management Co. MA Has $113.37 Million Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Congress Asset Management Co. MA cut its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 2.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 402,324 shares of the medical instruments supplier’s stock after selling 12,220 shares during the quarter. Congress Asset Management Co. MA’s holdings in West Pharmaceutical Services were worth $113,367,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Unigestion Holding SA acquired a new stake in West Pharmaceutical Services in the 1st quarter worth $970,000. Endurance Wealth Management Inc. lifted its holdings in shares of West Pharmaceutical Services by 1,351.2% during the 1st quarter. Endurance Wealth Management Inc. now owns 595 shares of the medical instruments supplier’s stock worth $168,000 after acquiring an additional 554 shares during the period. Stanley Laman Group Ltd. lifted its holdings in shares of West Pharmaceutical Services by 2.6% during the 1st quarter. Stanley Laman Group Ltd. now owns 1,948 shares of the medical instruments supplier’s stock worth $549,000 after acquiring an additional 50 shares during the period. IFM Investors Pty Ltd lifted its holdings in shares of West Pharmaceutical Services by 15.6% during the 1st quarter. IFM Investors Pty Ltd now owns 8,295 shares of the medical instruments supplier’s stock worth $2,337,000 after acquiring an additional 1,120 shares during the period. Finally, Natixis Advisors L.P. lifted its holdings in shares of West Pharmaceutical Services by 12.3% during the 1st quarter. Natixis Advisors L.P. now owns 56,917 shares of the medical instruments supplier’s stock worth $16,038,000 after acquiring an additional 6,217 shares during the period. Institutional investors own 92.55% of the company’s stock.

In other West Pharmaceutical Services news, insider Silji Abraham sold 2,171 shares of the business’s stock in a transaction dated Monday, May 10th. The shares were sold at an average price of $335.00, for a total value of $727,285.00. Following the completion of the transaction, the insider now directly owns 6,077 shares of the company’s stock, valued at $2,035,795. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

Shares of WST stock opened at $333.07 on Monday. West Pharmaceutical Services, Inc. has a 12-month low of $195.22 and a 12-month high of $339.65. The company has a market capitalization of $24.59 billion, a P/E ratio of 87.88, a P/E/G ratio of 3.86 and a beta of 1.13. The firm has a 50-day moving average price of $309.43 and a 200 day moving average price of $289.93. The company has a quick ratio of 2.23, a current ratio of 2.96 and a debt-to-equity ratio of 0.16.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 29th. The medical instruments supplier reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.63. West Pharmaceutical Services had a net margin of 14.69% and a return on equity of 19.01%. The firm had revenue of $670.70 million during the quarter, compared to the consensus estimate of $614.77 million. As a group, research analysts expect that West Pharmaceutical Services, Inc. will post 4.27 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 4th. Shareholders of record on Wednesday, July 21st will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.20%. The ex-dividend date of this dividend is Tuesday, July 20th. West Pharmaceutical Services’s dividend payout ratio is presently 20.99%.

Separately, Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $355.00 price objective for the company in a report on Wednesday, April 21st.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.

Featured Article: Nikkei 225 Index

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.